Enanta v. Pfizer: How One Digit Cost a Paxlovid Patent Its Priority Date

On June 23, 2026, the Federal Circuit affirmed that all claims of U.S. Patent 11,358,953, owned by Enanta Pharmaceuticals, are invalid. The compound at the center of the case is nirmatrelvir, the active antiviral ingredient in Pfizer's Paxlovid. The reason the patent failed traces back to a single character in a 2020 filing.

The '953 patent claims a genus of coronavirus protease inhibitor compounds built around Formula (VI-6a). Like most genus patents, its claims lean on a long definitions section that spells out exactly which chemical groups count as an allowed "substituent" wherever a claim says a position can be "optionally substituted." One entry in that list, in the issued patent, reads "-NHC(O)-C1-C12-alkyl": an amide-linked alkyl chain that can run from one to twelve carbons long.

Enanta's original provisional application, filed July 20, 2020, listed the same entry differently: "-NHC(O)-C2-C12-alkyl." The range starts at two carbons, not one. That difference of a single digit turned out to matter enormously, because Pfizer's actual compound, nirmatrelvir, carries a "-NHC(O)-C1-alkyl" group at that exact position: a one-carbon substituent, sitting right in the gap the provisional's range did not cover.

Pfizer's defense turned entirely on timing. A patent can only claim the priority date of an earlier provisional application if that provisional actually describes what the later patent claims. Pfizer argued the 2020 provisional never described a one-carbon substituent at all, only a two-to-twelve-carbon range that excluded it, so the '953 patent could not reach back to the 2020 filing date for that claim scope. Without that earlier date, Pfizer's own April 2021 disclosure of nirmatrelvir came first, and a compound already made public cannot later be patented by someone else.

Enanta's strongest counter-argument was not that the numbers matched. It was that the provisional contradicted itself. Before listing "C2-C12-alkyl" as an allowed substituent, the same document's own definitions section describes what "C2-C12 alkyl" and similar terms mean, and states in writing that such ranges cover groups with "one to twelve" carbon atoms, a phrase that does not match the numeral "2" sitting right next to it. Enanta's expert argued that a chemist reading that internal contradiction would recognize the numeral, not the words, as the actual typo, and would understand all along that a one-carbon version was meant.

The practical lesson sits squarely inside the kind of work genus-claim drafting and coverage analysis involves every day: a definitions section that lists dozens of allowed substituent classes is only as strong as the exact carbon counts, ranges, and exclusions written into each one. A single boundary set one carbon too high turned a real, valuable patent claim into one that could not reach the compound it was written to cover. Verifying that a claimed genus actually contains a specific real compound, structurally and exactly rather than by eye, is precisely the kind of check this case shows has real financial consequences attached to it.

Nothing here is a comment on the validity or drafting quality of any other patent, and nothing above should be read as legal advice. It is a summary of a public, precedential federal court opinion, based on the opinion's own text.